Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States.

Related Links:

AbstractResistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (C…

Source: Targeted OncologyCategory: Cancer & Oncology Source Type: research

CONCLUSION
Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but…

Source: Innovations in Clinical NeuroscienceCategory: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research

Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.

Author Affiliations open

1 McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada
2 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
3 Universitat Pompeu Fabra (UPF), Barcelona, Spain
4 CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
5 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
6 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA
7 Department of Economics, Brigham Young University, Provo, Utah, USA
8 Population Studies Division, Health Canada, Ottawa, Cana…

Source: EHP ResearchCategory: Environmental Health Authors: Tags: Research Source Type: research

Abstract
BackgroundSecond hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy‐related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B‐cell lymphoma. Although cutaneous T‐cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non‐Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program.
Me…

Source: International Journal of DermatologyCategory: Dermatology Authors: Tags: Report Source Type: research

Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.

Summary
Cancer‐related cognitive impairment (CRCI) is an important clinical problem for cancer patients and survivors. In this review, we summarize studies investigating the occurrence of impaired cognition in patients with haematological malignancies. Most published studies focus on survivors of childhood acute lymphoblastic leukaemia and primary central nervous system lymphoma. We also discuss studies conducted in acute myeloid leukaemia, myelodysplastic syndromes, chronic myeloid leukaemia, Hodgkin lymphoma (HL), non‐HL and chronic lymphocytic leukaemia. Although research in this area is still emerging, it appears t…

Source: British Journal of HaematologyCategory: Hematology Authors: Tags: Review Source Type: research

Summary
Cancer‐related cognitive impairment (CRCI) is an important clinical problem for cancer patients and survivors. In this review, we summarize studies investigating the occurrence of impaired cognition in patients with haematological malignancies. Most published studies focus on survivors of childhood acute lymphoblastic leukaemia and primary central nervous system lymphoma. We also discuss studies conducted in acute myeloid leukaemia, myelodysplastic syndromes, chronic myeloid leukaemia, Hodgkin lymphoma (HL), non‐HL and chronic lymphocytic leukaemia. Although research in this area is still emerging, it appears t…

Source: British Journal of HaematologyCategory: Hematology Authors: Tags: Review Source Type: research

This article summarizes the milestones in the development of venetoclax leading to this first approval for CLL.

Source: DrugsCategory: Drugs & Pharmacology Source Type: research

CONCLUSIONSDespite these increases, survival rates did not reach those observed for patients aged 50 to 59 years for any hematologic malignancy. Newer therapies and a better understanding of how to treat older patients have led to increased survival expectations for older patients with most hematologic malignancies, but an age‐related survival disparity persists. Cancer 2016. © 2016 American Cancer Society.

Source: CancerCategory: Cancer & Oncology Authors: Tags: Original Article Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image